Hepatitis Monthly
Official Journal of Research Center for Gastroenterology and Liver Diseases
Scopus by Title (Ref)
1. Changes in the distribution pattern of hepatitis c virus genotypes among chronic hepatitis patients: A cross-sectional study
- Kazemi R. , et al.
2. The predictive factors for favorable outcomes of peginterferon and ribavirin combination therapy in HCV-infected patients
- Moayedi J. , et al.
3. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population
- Ramezani A. , et al.
4. The role of hepatic progenitor cells in predicting response to therapy in Egyptian patients with chronic hepatitis C, genotype 4
- Helal T.E.A. , et al.
5. Psychiatric side effects of pegylated interferon-α and ribavirin therapy in iranian patients with chronic hepatitis c: A meta-analysis
- Davoodi L. , et al.
6. The evaluation of interferon lambda 4 rs368234815 as a predictor factor in treated patients with chronic hepatitis C genotype 1a infection
- Jalilian S. , et al.
7. IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C
- Sedighimehr P. , et al.
8. Risk factors for migraine attacks in patients undergoing treatment for hepatitis C
- Salesi R. , et al.
9. Recommendations for the clinical management of hepatitis C in Iran: A consensus-based national guideline
- Alavian S.M. , et al.
10. Prevalence of hepatitis C virus genotypes among patients in countries of the eastern mediterranean regional office of WHO (EMRO): A systematic review and meta-analysis
- Sadeghi F. , et al.
11. Hepatitis C therapy-related haematological side effects are associated with treatment outcome
- Vukovic V.R. , et al.
12. Epidemiology of hepatitis C virus in Iran
- Taherkhani R. , et al.
13. Efficacy and tolerability of peginterferon alpha-2a and peginterferon alpha-2b in Iranian patients with chronic hepatitis C
- Pouresmaeeli M. , et al.
14. Interferon-λpolymorphisms and response to pegylated interferon in Iranian hepatitis C patients
- Haj-sheykholeslami A. , et al.
15. High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of iranian patients to chronic hepatitis C treatment
- Fateh A. , et al.
16. Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients
- Bokharaei-Salim F. , et al.
17. Predicting the outcomes of combination therapy in patients with chronic hepatitis c using artificial neural network
- Aval F.S. , et al.
18. Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C
- Sadeghi F. , et al.
19. Interleukin-28b (rs12979860) gene variation and treatment outcome after peginterferon plus ribavirin therapy in patients with genotype 1 of hepatitis C virus
- Kalantari H. , et al.
20. Evaluated outcomes in patients with chronic hepatitis C
- Ashtari S. , et al.
21. Hepatitis C and why the treatment is needed now? The summary report from the cross-border symposium of the 5th Tehran Hepatitis Congress May 2013
- Ebrahimi Daryani N. , et al.
22. Plasma zinc level in hepatitis C patients with or without beta thalassemia major; Is there any difference?
- Abbasinazari M. , et al.
23. Some considerations about cardiac toxicity of combination therapy for chronic hepatitis C
- Karbasi-Afshar R. , et al.